Drive Outcomes
with At-Home Testing

Raise adherence, reduce costs, and improve patient health
by shifting testing from the lab to the home.
Get a Custom ROI Report
From 0% to 72% Adherence 1
The majority of at-risk Americans do not take their annual urine test. Reach the untested population by allowing them to self-test when it's most convenient, without leaving home.
ACR Test Kit Sent to Patient's Homes
Send

We send ACR test kits2 directly to patients' homes with their prior consent

Patient Self-Tests Using Smartphone and Kit
Test

Patients self-test using our test kit and app, snapping a picture with their phones

Test Results Reviewed by Physician
Review

Results are analyzed, and available immediately for the doctor to review

Smartphone-Powered Kidney Testing

Promote early detection while significantly boosting revenue and quality performance. Our CKD Early Detection Service has demonstrated significant gains for health plans by preventing progression of the disease, reducing the total cost of care, and improving risk scoring. Based on an actuarial evaluation, health plans can earn a positive ROI3 within two years by increasing test adherence and identifying CKD earlier.
Get a Custom ROI Report
This new test has the potential to help millions of patients find out if they have CKD while there is still time to prevent progression to kidney failure."
Kerry Willis, PhDChief Scientific Officer, NKF
Kerry Willis, PhD

Get Your Custom Report

Please fill in the form to receive a detailed cost-effectiveness analysis for your health plan, including:

  • A breakdown of your at-risk population
  • Drill-down of your potential net gains 
  • ROI calculation for your total population
  • Sensitivity analysis of your cost-savings potential
By providing this information, you consent to receive relevant content from Healthy.io. For more information, visit our Privacy Policy.
By providing this information, you consent to receive relevant content from Healthy.io. For more information, visit our Privacy Policy.

1. Validated in a rollout with Geisinger Health, among consented untested population. BMC Nephrol 20, 132 (2019). https://doi.org/10.1186/s12882-019-1324-z

2. FDA-cleared for professional use. Home-testing device is currently limited to investigational use in the United States.

3. Outcomes derived from a model performed by an external credentialed actuary. The model is based on an actuarial evaluation of medical and pharmacy claims data representing 4.9 million members managed under Medicare Advantage and 12.7 million members managed under commercial plans. Net gain and ROI is calculated assuming proper management and treatment of the disease after diagnosis.

SUBSCRIBE TO OUR BLOG

Get the latest insights on digital health and
expanding access to care

We respect your privacy

Copyright © 2020 Healthy.io. All rights reserved.